324 related articles for article (PubMed ID: 37117135)
81. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
82. Practical cardiovascular imaging approach to diagnose immune checkpoint inhibitor myocarditis.
Kondapalli L; Medina T; Groves DW
Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):372-374. PubMed ID: 33367684
[TBL] [Abstract][Full Text] [Related]
83. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review.
Liu YF; Zhang ZC; Wang SY; Fu SQ; Cheng XF; Chen R; Sun T
Int Immunopharmacol; 2022 Sep; 110():108900. PubMed ID: 35753122
[TBL] [Abstract][Full Text] [Related]
84. Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity.
Cluxton C; Naidoo J
Curr Oncol; 2023 Jul; 30(7):6862-6871. PubMed ID: 37504362
[TBL] [Abstract][Full Text] [Related]
85. Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.
Sobol I; Chen CL; Mahmood SS; Borczuk AC
Arch Pathol Lab Med; 2020 Nov; 144(11):1392-1396. PubMed ID: 32150459
[TBL] [Abstract][Full Text] [Related]
86. Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Miller EJ; Rose TL; Maughan BL; Milowsky MI; Bilen MA; Carthon BC; Gao X; Rapisuwon S; Zhao Q; Yu M; Agarwal N; Galsky MD
Cancer; 2024 May; 130(9):1642-1649. PubMed ID: 38180804
[TBL] [Abstract][Full Text] [Related]
87. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
88. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
Kejamurthy P; Devi KTR
Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
[TBL] [Abstract][Full Text] [Related]
89. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
90. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
91. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
Jiang Y; Zhao X; Fu J; Wang H
Front Immunol; 2020; 11():339. PubMed ID: 32226426
[TBL] [Abstract][Full Text] [Related]
92. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
Yin J; Wu Y; Yang X; Gan L; Xue J
Front Immunol; 2022; 13():830631. PubMed ID: 35464480
[TBL] [Abstract][Full Text] [Related]
93. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract][Full Text] [Related]
94. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
95. Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy.
He M; Yang T; Wang Y; Wang M; Chen X; Ding D; Zheng Y; Chen H
Adv Healthc Mater; 2021 May; 10(9):e2002104. PubMed ID: 33709564
[TBL] [Abstract][Full Text] [Related]
96. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
97. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
98. Novel targets for immune-checkpoint inhibition in cancer.
Borgeaud M; Sandoval J; Obeid M; Banna G; Michielin O; Addeo A; Friedlaender A
Cancer Treat Rev; 2023 Nov; 120():102614. PubMed ID: 37603905
[TBL] [Abstract][Full Text] [Related]
99. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus.
Liao D; Liu C; Chen S; Liu F; Li W; Shangguan D; Shi Y
Int Immunopharmacol; 2023 Sep; 122():110414. PubMed ID: 37390646
[TBL] [Abstract][Full Text] [Related]
100. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]